It Depends On The Subvariant You Have.
New SARS-CoV-2 variants will probably continue to emerge in the future. Therapeutic neutralizing antibodies are one of the forefront treatments. We believe that rapid evaluation of their efficacy against new variants will be an important insight toward the end of pandemic.
In this study, we evaluated the sensitivity of the Omicron BA.2.75 subvariant to 10 therapeutic monoclonal antibodies: adintrevimab, bamlanivimab, bebtelovimab, casirivimab, cilgavimab, etesevimab, imdevimab, regdanvimab, sotrovimab & tixagevimab.
#adintrevimab, #bamlanivimab, #casirivimab, #etesevimab & #imdevimab did not work against all Omicron subvariants tested including BA.2, BA.4/5 and BA.2.75.
#bebtelovimab exhibited robust antiviral effect against BA.2 & BA.4/5, but BA.2.75 was more resistant to this antibody than BA.2 (21-fold) and BA.4/5 (26-fold), suggesting that #bebtelovimab may not be a good choice to combat BA.2.75 infection.
Similar to BA.4/5, BA.2.75 was more resistant to #cilgavimab than BA.2.
#sotrovimab, #tixagevimab & #regdanvimab were not efficiently antiviral against BA.2 and BA.4/5. However, these 3 antibodies were functional against BA.2.75, suggesting that these 3 monoclonal antibodies can be used for anti-BA.2.75 therapy.